BPC-157 in research: the pentadecapeptide and what the literature actually shows

BPC-157 is one of the most talked-about peptides in preclinical repair research, and also one of the most misunderstood. The name is short for Body Protection Compound-157, a synthetic chain of fifteen amino acids. Its sequence was pulled from a larger protein first characterised in human gastric juice, which is where the body-protection framing comes from. What makes it interesting to laboratories is its reported stability in acidic conditions and the sheer breadth of tissue-repair models it has appeared in. What makes it tricky is that almost all of that work sits in cell culture and animal models, not in people.

For laboratory research use only. Not for human or veterinary use.

What the molecule actually is

BPC-157 is a pentadecapeptide, which simply means a peptide of fifteen residues. Its one-letter sequence is GEPPPGKPADDAGLV, built entirely from standard L-amino acids with free ends at both the N- and C-terminus. There is no ring structure, no acetyl cap and no unusual residue. That plainness is part of the story. The parent protein it derives from is large, and BPC-157 represents a partial sequence that researchers isolated and found to be unusually robust in the low-pH environment of the stomach, where many peptides fall apart within minutes.

Because it carries no metal, no lipid tail and no D-amino acids, it is a straightforward linear peptide from a chemistry standpoint. Its measured molecular weight is roughly 1419.5 g/mol for the free base. As with most research peptides, the exact mass on a certificate of analysis can shift depending on whether the material is supplied as a trifluoroacetate or acetate salt, so the number on a lot record is the one that counts, not the free-base figure quoted in general references.

Verified molecule

• Sequence (1-letter): GEPPPGKPADDAGLV
• Molecular formula: C62H98N16O22
• Molecular weight: 1419.5 g/mol (free base)
• CAS number: 137525-51-0
• Class: linear pentadecapeptide, standard L-amino acids, free N- and C-termini

What the literature examines

Most of the mechanistic interest centres on two overlapping ideas. The first is a link to nitric oxide signalling: several groups report that the peptide interacts with the NO system in a way that shifts vascular tone and blood-vessel formation in their models. The second is angiogenesis routed through vascular endothelial growth factor receptor 2 (VEGFR2), the receptor that steers new capillary growth. In cultured cells, exposure to the peptide has been associated with faster migration of fibroblasts and endothelial cells, the two populations that rebuild connective tissue and vessels after damage.

From there the preclinical literature branches widely. Rodent models of tendon, ligament, muscle and gut injury make up a large share of the published reports, alongside work on the gastrointestinal lining that echoes the peptide's gastric origin. Some groups have also reported effects along the gut-brain axis and on tissue exposed to toxins, which is a big claim for a single fifteen-residue sequence. The recurring theme is tissue repair and vascular support rather than any one narrow target.

That breadth is genuinely unusual, and it is also the reason to stay sceptical. A compound that appears to do many things across many tissues in rodents has not, on that basis alone, shown any of them in controlled human work. The most careful reviews frame the mechanistic picture as promising and incomplete rather than settled, and they are explicit that the pathways described in animals still need mapping in higher systems.

The acid stability is worth a sentence of its own. Many peptides are degraded quickly by the enzymes and low pH of the digestive tract, which sharply limits how they can be studied. BPC-157 is repeatedly described as unusually stable under those conditions, and that robustness is a large part of why the gastric-origin story attracted attention: a fragment that survives where its neighbours fall apart is easier to work with and easier to justify studying in gut models. Whether that stability fully carries across every buffer and preparation is itself something researchers check rather than assume, which is why lot-level analysis keeps coming up.

Where it came from

BPC-157 came out of work led by Predrag Sikiric and colleagues in Croatia, who described the parent Body Protection Compound and its active fragment through the 1990s and 2000s. Their long series of papers built the peptide's reputation in the repair literature and tied it to the nitric oxide system. A 2014 review in Current Pharmaceutical Design pulled much of that mechanistic work together. Interest has continued since, including a 2025 overview in Pharmaceuticals that surveyed the peptide's reported actions and, usefully, the gaps that remain in the evidence.

Honest limitations

The single biggest caveat is the evidence base. The overwhelming majority of BPC-157 data comes from rodents and cell culture, often from a small cluster of research groups. Well-controlled human trials are essentially absent from the peer-reviewed record, so any claim that carries a rodent repair finding straight over to people is running well ahead of the data. Pharmacokinetics are also poorly defined, and stability figures vary between reports and preparations, which makes cross-study comparison harder than it looks.

There are practical caveats too. Because the peptide is popular, the market carries material of uneven purity, and independent testing has repeatedly turned up mislabelled or degraded product. For a laboratory, that means identity and purity should be confirmed against a certificate of analysis and, ideally, independent mass spectrometry rather than taken on trust. None of this is a verdict on whether the peptide works. It is a reminder that the interesting signals are early-stage and, so far, almost entirely non-human.

Common questions

What is BPC-157?

It is a synthetic fifteen-residue peptide whose sequence derives from a protein found in human gastric juice. In research settings it is studied for links to nitric oxide signalling, angiogenesis and connective-tissue repair, almost entirely in cell and animal models.

How does BPC-157 differ from TB-500?

Both are studied in tissue-repair models, but they are chemically unrelated. BPC-157 is a fifteen-residue sequence tied to gastric protection and nitric oxide signalling, while TB-500 is a short acetylated fragment of thymosin beta-4 that works through actin binding. They share a research theme, not a structure or a mechanism.

How is it stored?

Lyophilised BPC-157 is typically kept frozen and protected from light and moisture, with reconstituted material held cold and used within a short window. The exact window belongs on the lot certificate of analysis rather than in a general article, since it depends on the buffer and salt form of the specific batch.

References

1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and the NO-system relation. Current Pharmaceutical Design. 2014.
2. Jozwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals (Basel). 2025.